Genetic Screen in a Pre-Clinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities.
Jack FreelandMaria MuñozEdmond F O'DonnellJustin LangermanMorgan DarrowJessica BergonioJulissa Suarez-NavarroSteven W ThorpeRobert J CanterRobert Lor RandallKathrin PlathKermit L CarrawayOwen N WitteThomas Glen GraeberJanai R Carr-AscherPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Transcriptional co-analysis of TCGA patient samples to YAP1 and KRAS model tumors support that these sarcoma subtypes lie along a spectrum of disease and adds guidance for further transcriptome-based refinement of sarcoma subtyping. This approach can be used to begin to understand pathways and mechanisms driving human sarcoma development, the relationship between sarcoma subtypes and to identify and validate new therapeutic vulnerabilities for this aggressive and heterogeneous disease.